ISCB43: Programme Overview *programme is subject to change

Sunday 21st August 2022

Time	Pre-conference course 2.15	Pre-conference course 2.16	Pre-conference course 2.14	Pre-conference course 2.14
09.00-10.30	**Full day Shortcourse 1: Introduction to Machine learning for health questions** *Dr Paul Kirk, University of Cambridge*	**Full day Shortcourse 2: Design and Analysis of Precision Medicine trials** *Prof James Wason, Newcastle University, and Haiyan Zheng, University of Cambridge*	**Half day Shortcourse 3: Statistical integration of multiple omics datasets using OmicsPLS** *Said el Bouhaddani, UMC Utrecht and Jeanine Houwing-Duistermaat, University of Bologna*	
10.30-11.00	**BREAK**			
11.00-12.30	**Full day Shortcourse 1: Introduction to Machine learning for health questions**	**Full day Shortcourse 2: Design and Analysis of Precision Medicine trials**	**Half day Shortcourse 3: Statistical integration of multiple omics datasets using OmicsPLS**	
12.30-13.30	**LUNCH**			
13.30-15.00	**Full day Shortcourse 1: Introduction to Machine learning for health questions**	**Full day Shortcourse 2: Design and Analysis of Precision Medicine trials**		**Half day Shortcourse 4: Introduction to the tidyverse** *Prof John Thompson, University of Leicester*
15.00-15.30	**BREAK**			
15.30-17.00	**Full day Shortcourse 1: Introduction to Machine learning for health questions**	**Full day Shortcourse 2: Design and Analysis of Precision Medicine trials**		**Half day Shortcourse 4: Introduction to the tidyverse**

Monday 22nd August 2022

Time	G.41	G.56	G.06	1.17	2.16
09.00-10.30	**Invited 1: Machine learning with small data** *30min presentation each* **IN1.1 Structured priors for improving treatment response prediction in cancer pharmacogenomic screens** Manuela Zucknick **IN1.2 Sequential learning of regression models through penalized estimation** Wessel van Wieringen **IN1.3 Interpretable deep generative approaches for small omics data-sets** Moritz Hess	**Parallel Session 1: Adaptive Designs**	**Parallel Session 2: Causal Inference**	**Parallel Session 3: Missing data**	**Parallel Session 4: Survival data**
		09.00- 09.18: **S1.1 Adaptive enrichment designs with a continuous biomarker** *Nigel Stallard, University of Warwick*	09.00- 09.18: **S2.1 Using many invalid instrumental variables to tighten inference on causal effects** *Ashish Patel, MRC Biostatistics Unit*	09.00- 09.18: **S3.1 Multiple imputation for the Fine-Gray model: an approach based on the subdistribution process** *Edouard F Bonneville, Leiden University Medical Center*	09.00- 09.18: **S4.1 General independent censoring in event-driven trials with staggered entry** *Jasmin Rühl, University of Augsburg*
		09.19-09.36: **S1.2 A Bayesian multi-arm multi-stage design incorporating information about treatment ordering** *Alessandra Serra, MRC Biostatistics Unit*	09.19-09.36: **S2.2 Sensitivity Analysis of Causal Effects in Observational Studies** *Md. Abdul Basit, Institute of Statistical Research & Training, University of Dhaka*	09.19-09.36: **S3.2 Record linkage with complex correlation structures** *Michel Hof, Amsterdam University Medical Center*	09.19-09.36: **S4.2 Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s)** *Kaspar Rufibach, F. Hoffmann-La Roche*
		09.37-09.54: **S1.3 Recommending a timing for a stop for efficacy in group sequential trials with a survival endpoint** *Akane Yamakawa, Foundation for Biomedical Research and Innovation at Kobe*	09.37-09.54: **S2.3 Investigating inequalities in cancer survival through mediation analysis with limited interventions** *Sarah Booth, University of Leicester*	09.37-09.54: **S3.3 Quantitative bias analysis for unmeasured confounding: Review of software for regression** *Emily Kawabata, University of Bristol*	09.37-09.54: **S4.3 Stratified modestly-weighted log-rank tests in settings with delayed separation of survival curves** *Dominic Magirr, Novartis*
		09.55-10.12: **S1.4 Two-stage designs for clinical**	09.55-10.12: **S2.4 Inferring the Effect Direction in Genetic Association Studies**	09.55-10.12: **S3.4 Sensitivity analysis for calibrated weighted**	09.55-10.12: **S4.4 Restricted mean survival time regression model**

		trials with small sample sizes *Nico Bruder, University of Heidelberg*	*Sharon Lutz, Harvard Medical School*	**estimators under non-ignorable dropout** *Li Su, University of Cambridge*	**with time-dependent covariates** *Chengfeng Zhang, Southern Medical University*
		10.13-10.30: **S1.5 Cross-validated risk scores adaptive enrichment design** *Svetlana Cherlin, Newcastle University*	10.13-10.30: **S2.5 Personalized Biopsy Schedules Using Cause-specific Interval-censored Joint Models** *Zhenwei Yang, Erasmus Medical Center*	10.13-10.30: **S3.5 Standard and reference-based imputation methods based on conditional mean imputation** *Marcel Wolbers, Roche*	10.13-10.30: **S4.5 Efficient estimation of joint models for multivariate longitudinal and survival data using INLA** *Denis Rustand, King Abdullah University of Science and Technology*
10.30-11.00	**BREAK**				
11.00-12.30	**Invited 2: Master protocols** *22min presentation each* **IN2.1 Statistical issues in design and analysis of master protocols** *James Wason* **TBC IN2.2** *Franz Koenig* **IN2.3 Bayesian Basket Trial Design with False Discovery Rate Control** *Emily Zabor*	**Parallel Session 5: Software Engineering**	**Parallel Session 6: Cluster Trials**	**Parallel Session 7: High dimensional data**	**Parallel Session 8: Lightning poster talks 1**
		11.00-11.18: **S5.1 Introduction from the Academic Perspective** *Martin Shaw, University of Glasgow*	11.00-11.18: **S6.1 Decaying correlation parameter values obtained from previously analysed cluster randomised trials** *Jessica Kasza, Monash University*	11.00-11.18: **S7.1 Rank-based Bayesian variable selection for genome-wide transcriptomic analyses** *Emilie Eliseussen Ødegaard, University of Oslo*	*3min presentation each* **P6 A comparison of methods for estimating dichotomous treatment effects: a simulation study** **P7 A comparison of strategies for selecting auxiliary variables for multiple imputation** **P9 A Flexible Copula Model for Bivariate**
		11.19-11.36: **S5.2 Introduction from the Industry Perspective** *Daniel Sabanes Bove, Roche*	11.19-11.36: **S6.2 The staircase cluster randomised trial design: a pragmatic alternative to the stepped wedge design** *Kelsey Grantham, Monash University*	11.19-11.36: **S7.2 More than meets the eye: Visualising temporal patterns in time-series single-cell RNA-seq data** *Laia Canal Guitart, University of Freiburg*	

	IN2.4 On the Lung Cancer Master Protocol (Lung-MAP) *Mary Redman*	11.37-12.30: **S5.3 Panel discussion** *Armin Schueler, Merck* *Andy Nicholls, GSK* *Anne-Laure Boulesteix, LMU Munich* *Alessandro Gasparini, Karolinska* *Martin Shaw, University of Glasgow* *Daniel Sabanes Bove, Roche*	11.37-11.54: **S6.3 Sample size calculations for cluster randomised trials using assurance** *Kevin Wilson, Newcastle University*	11.37-11.54: **S7.3 Prior distributions for structured covariance matrices** *Oludare Samuel Ariyo, Federal University of Agriculture, Abeokuta, Nigeria*	**Survival Data with Dependent Censoring** **P10 A lean additive frailty model: with an application to clustering of melanoma in Norwegian families** **P11 A multi-arm multi-stage platform design that allows pre-planned addition of arms while still control** **P13 A novel scoring system for diagnosis of Tuberculous Meningitis: a Bayesian Latent Class Analysis** **P17 A review of early phase dose-finding clinical trials with incomplete follow-up for toxicity consider** **P25 Analysis of concentration-time-response data in cell-based compound profiling** **P34 Bayesian Inference on Multilevel Semi-**
			11.55-12.12: **S6.4 Ratio-of-ratio estimator of direct intervention effect in cluster-randomized trials** *xiangmei Ma, Duke-NUS Medical School*	11.55-12.12: **S7.4 Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso** *Wencan ZHU, AgroParisTech*	
			12.13-12.30: **S6.5 Estimating the intervention effect using restricted mean survival time in a cluster randomized trial** *Floriane Le Vilain--Abraham, Université de Tours*	12.13-12.30: **S7.5 Fast marginal likelihood estimation of group-adaptive elastic net penalties** *Mark van de Wiel, Amsterdam University Medical Center*	

					continuous Pharmaceutical expenditure Data P37 Bayesian nonparametric methods for prediction of missing data P39 Benchmarking Six Variant Callers for Detecting Low Frequency Variants in Circulating Tumour DNA P42 Causal effects of chemotherapy dose intensity on survival outcome through Marginal Structural Models P43 Causal forests for uncovering treatment effect heterogeneity and data driven subgroups in trials P48 Combining deep learning and dynamic modelling to infer disease trajectories of patients with SMA

					P49 Combining non-adherence and mediation in a unified causal analysis **P57 Comparison of statistical methods for the analysis of SF-36 in RCTs: an empirical analysis** **P62 Correlates of Protection Analysis of Vaccines in a Pre-Exposed Population**
12.30-13.30	**LUNCH**				
13.30-15.00	**Invited 3: Best practices in statistical simulation and computing** *30min presentation each* **IN3.1 On the researchers' degree of freedom in comparison studies** *Anne-Laure Boulesteix* **IN3.2 Neutral schmeutral: fair comparisons and simulation-study estimands** *Tim Morris*	**Parallel Session 9: Meta-analysis** 13.30-13.48: **S9.1 A New Visualisation for Component Network Meta-Analysis: The Circle plot** *Elnaz Saeedi, University of Leicester* 13.49-14.06: **S9.2 The usual method of estimating weights for studies in meta-analyses is biased** *Stephen Walter, McMaster University*	**Parallel Session 10: Ageing** 13.30-13.48: **S10.1 4-step longitudinal analysis of latent traits derived from measurement scales in chronic diseases** *Tiphaine Saulnier, University of Bordeaux* 13.49-14.06: **S10.2 Biological age cannot be estimated with cross-sectional data** *Marije Sluiskes, Leiden University Medical Center*	**Parallel Session 11: Communication of survival methods** 13.30-13.48: **S11.1 Different multi-state structures when studying antidepressive medication in women with breast cancer** *Nikolaos Skourlis, Karolinska Institute* 13.49-14.06: **S11.2 Fair comparison of cause-specific and relative survival by accounting for informative censoring** *Molly Wells, University of Leicester*	**Parallel Session 12: Lightning poster talks 2** *3min presentation each* **P65 Developing a Patient Engagement Framework for Quality Improvement in Healthcare Services** **P70 Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: A Marginalized 2-Part Model** **P72 Discrimination and calibration of atrial**

	IN3.3 Step-by-step guidance on best practices in statistical computing *Ricardo Sanchez*	14.07-14.24: **S9.3 Ranking treatments on multiple outcomes and trade-off between benefit and harms** *Virginia Chiocchia, Institute of Social and Preventive Medicine*	14.07-14.24: **S10.3 Multimorbidity pattern and risk of dementia: an 11-year follow-up study using the UK Biobank cohort** *Mizanur Khondoker, University of East Anglia*	14.07-14.24: **S11.3 Cox regression with linked data** *Thanh Huan VO, Institute of Research and Technology - b-com*	**fibrillation predictions obtained by CNN and XGB from ECG** **P84 Exploratory analyses in etiologic research and considerations for assessment of credibility** **P90 Glycemic control prior to cancer incidence and mortality among patients with type 2 diabetes** **P91 Handling multivariable missing data in causal mediation analysis with a single mediator** **P93 Hypothesis testing for CCA given prespecified sparsity levels** **P97 Impact of ALS subtypes on disease progression: A continuous temporal multivariate approach** **P101 Improving Signal Detection in Small Pharmacovigilance**
		14.25-14.42: **S9.4 Using cutting-edge methodology to maximise the value of Individual Participant Data meta-analysis** *David Fisher, UCL*	14.25-14.42: **S10.4 Expected life years compared to the general population** *Maja Pohar Perme, University of Ljubljana*	14.25-14.42: **S11.4 Evaluating cancer screening programmes using survival analysis** *Bor Vratanar, University of Ljubljana*	
		14.43-15.00: **S9.5 A Simulation Study Comparing Methods for Meta-Analysis of Time-to-Event Outcomes** *Theodosia Salika, University College London*	14.43-15.00: **S10.5 Recoverability and estimation of causal effects under typical multivariable missingness mechanisms** *Jiaxin Zhang, the University of Melbourne; Murdoch Children's Research Institute*	14.43-15.00: **S11.5 Assessing lead time bias due to mammography screening on estimates of loss in life expectancy** *Elisavet Syriopoulou, Karolinska Institutet*	

					Datasets – A New Pipeline Approach **P102 Imputation of MNAR variables in an individual participant data meta-analysis** **P107 Learning treatment effect in neurodegenerative diseases with a Bayesian mixed-effect model** **P108 Likelihood-based inference in control risk regression with study-specific covariates** **P111 Machine learning methodologies for modelling of time-to-event endpoints in Prostate Cancer** **P115 Methods for modelling the multi-state natural history of rare diseases using disparate IPD sources** **P119 Mixed-effects location-scale models for**

					within-individual variability in cystic fibrosis **P122 Modelling disease transitions in multimorbidity via multistate models** **P123 Modelling non-linear time-varying intervention effects on recurrent events**
15.00-15.30	**BREAK**				
15.30-16.00	**Conference opening**				
16.00-17.00	**President's invited speaker:** Prof John Carlin				
17.00-19.00	**17:00-19.00: Welcome reception** **(At conference venue)** **17.15-18.00: Networking social for online attendees (online)**				

Tuesday 23rd August 2022

Time	G.41	G.56	G.06	1.17	2.16
09.00-10.30	**Invited 4: Ageing** *25min presentation each followed by 15min discussion* **IN4.1 Translating models of ageing into routine clinical practice.** Andrew Clegg **IN4.2 A new statistical framework for biological age estimation** Rodriguez Girondo **IN4.3 From variant to function: Identification and characterisation of genetic variants linked to human longevity** Joris Deelen Discussant: Jeanine Houwing-Duistermaat	**Parallel Session 13: COVID-19**	**Parallel Session 14: Basket trials**	**Parallel Session 15: Machine learning for health applications**	**Parallel Session 16: Lightning poster talks 3**
		09.00- 09.18: **S13.1 Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials** *Hege Michiels, Ghent University*	09.00- 09.18: **S14.1 Sample size determination in basket trials borrowing information across subsets** *Haiyan Zheng, University of Cambridge*	09.00- 09.18: **S15.1 Uncertainty measures of survival predictions with neural networks applied to molecular data** *Elvire Roblin, Inserm U1018 - MICS CentraleSupelec*	*3min presentation each* **P124 Modelling the impact of SARS-CoV-2 vaccination in a cohort of patients hospitalized for COVID-19** **P132 Outlier study detection in a meta-analysis of clinical trials** **P134 Pattern Identification in Biomedical Markers of a Mixed Type** **P135 Performance metrics for models predicting individualized treatment effect of patients** **P137 Performance of methods for meta-analysis of incremental predictive value: a comparison study**
		09.19-09.36: **S13.2 The impact of nosocomial bacterial co-infections on the mortality of COVID-19 patients** *Maiju Pesonen, Oslo Centre for Biostatistics and Epidemiology*	09.19-09.36: **S14.2 Information Borrowing in Basket Trials: A Proposal and Evaluation** *Libby Daniells, Lancaster University*	09.19-09.36: **S15.2 Subgroup discovery with survival decision trees: detection of early conversion in Alzheimer's stages** *Martin Prodel, HEVA*	
		09.37-09.54: **S13.3 Covid-19: waning immunity and the booster dose effect in Israel** *Micha Mandel, Hebrew University of Jerusalem*	09.37-09.54: **S14.3 Bayesian information sharing methods for a longitudinal basket trial** *Lou Whitehead, Newcastle University*	09.37-09.54: **S15.3 Spatio-Temporal Functional Principal Component Analysis** *Sonia Dembowska, University of Leeds*	
		09.55-10.12: **S13.4 Assessing the impact of elevated population**	09.55-10.12: **S14.4 Bayesian modelling strategies for borrowing**	09.55-10.12: **S15.4 Causal machine learning and use of sample splitting in**	

		mortality rates due to Covid-19 on relative survival *Rachael Stannard, University of Leicester*	**of information in randomised basket trials** *Luke Ouma, Newcastle University*	**settings with high-dimensional confounding** *Susan Ellul, University of Melbourne and Murdoch Children's Research Institute*	**P138 Performance of the P30 measure for assessing the accuracy of estimating glomerular filtration rate** **P140 Predicting multidrug resistance in neutropenic cancer patients with bloodstream infection** **P141 Prediction of clinical trial cycle times with Bayesian Model Averaging** **P145 Quantitative decision-making in the context of early-phase biomarker-adaptive designs** **P151 Repeatability of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI): A Systematic Review** **P152 Reporting of sequential multiple assignment randomized trial design studies: a systematic review**
		10.13-10.30: **S13.5 Estimation of incubation time in relation to quarantine length: the impact of distributional assumptions** *Vera Arntzen, Leiden University*	10.13-10.30: **S14.5 Using Empirical Bayes Power Priors for Designing Basket Trials** *Lukas Baumann, University of Heidelberg*	10.13-10.30: **S15.5 Modeling high-dimensional interaction problems with the pliable lasso** *Theophilus Quachie Asenso, University of Oslo*	

					P157 Sample size estimation in RCT with annualized relapse rates can be improved: a review **P162 Simulating the Impact of Intercurrent Events and Missing Data for Clinical Trials** **P163 Simulation study of within-subject variability estimation: linear mixed effects & variogram analyses** **P171 Survival of Danish twins born 1870-2000** **P175 The Evaluation of Repeated Events in the PLEASANT dataset** **P176 The Hierarchical Bias-Corrected Meta-Analysis Model** **P178 The number of cases, mortality and treatments of viral hemorrhagic fevers: a systematic review**

					P104 Investigating use of Random Forest Clustering with multi-omics data to identify novel TNBC clusters **P120 Model selection for multi-state models in medical research** **P174 The effect of sample size on selecting a satisfactory descriptive model with the MFP approach** **P188 Multinomial prediction models for methotrexate outcomes in rheumatoid arthritis** **P126 Monitoring time to event in medical registry data using CUSUMs based on excess hazard models** **P142 Predictive modeling approaches to personalized medicine: a comparison of regression-based methods**
10.30-11.00	**BREAK**				

11.00-12.30	**Invited 5: Student Awardees** *22mins presentation each* **IN5.1 Spatial Dependence Modeling of Latent Susceptibility and Time to Joint Damage in Psoriatic Arthritis** - *Fangya Mao* **IN5.2 Sharing information across patient subgroups to draw conclusions from sparse treatment networks** - *Theodoros Evrenoglou* **IN5.3 Triangulating Instrumental Variable, confounder adjustment and Difference-in-Difference methods for comparative effectiveness research in observational data** - *Laura Guedemann* **IN5.4 Random survival forests for competing causes with multivariate longitudinal endogenous**	**Parallel Session 17: Competing risks**	**Parallel Session 18: Personalized Medicine**	**Parallel Session 19: Clinical Trials**	**Parallel Session 20: Heterogeneity in effects**
		11.00-11.18: **S17.1 Estimands for Recurrent and Terminal Events: Methods, Issues and Recommendations** *Alexandra Buehler, University of Waterloo*	11.00-11.18: **S18.1 Resampling Methods to Control the Family Wise Error Rate for Dual Biomarker Threshold Identification** *Ben Lanza, University of Warwick*	11.00-11.18: **S19.1 Should the two-trial paradigm still be the gold standard in drug assessment?** *Stella Jinran Zhan, University of Warwick*	11.00-11.18: **S20.1 Evaluation of mental health patients' diagnostic-therapeutic paths through state sequences analysis** *Laura Savare, Politecnico di Milano*
		11.19-11.36: **S17.2 Separable Effects of Baseline Exposure in Multi-State Models** *Niklas Maltzahn, Oslo Centre for Biostatistics and Epidemiology*	11.19-11.36: **S18.2 Personalized optimal treatment timing through multi-state modelling and microsimulation** *Caterina Gregorio, Politecnico di Milano*	11.19-11.36: **S19.2 Conditional Drug Approval with the Harmonic Mean Chi-Squared Test** *Charlotte Micheloud, University of Zurich*	11.19-11.36: **S20.2 Causal DART: A non-parametric Bayesian approach to estimate heterogeneous treatment effects.** *Ashwini Venkatasubramaniam, The Alan Turing Institute*
		11.37-11.54: **S17.3 Externally Validating Clinical Dynamic Prediction Joint Models for Localised Prostate Cancer** *Harry Parr, The Institute of Cancer Research*	11.37-11.54: **S18.3 Methods for estimating personalized treatment recommendations with extensions to survival data** *Jennifer Hellier, King's College London*	11.37-11.54: **S19.3 Frequentist and Bayesian approaches to rescuing disrupted trials** *Richard Emsley, King's College London*	11.37-11.54: **S20.3 Adjusting for time of positive test when estimating the risk of a post-infection outcome** *Shaun Seaman, University of Cambridge*
		11.55-12.12: **S17.4 Integrating relative survival in multi-state models—a non-parametric approach**	11.55-12.12: **S18.4 Drugs combinations screening using a Bayesian ranking approach based on dose-response models**	11.55-12.12: **S19.4 The role of grace periods in comparative effectiveness studies of different medications**	11.55-12.12: **S20.4 Disentangling interactions between components of complex health interventions**

	covariates - *Anthony Devaux*	*Damjan Manevski, University of Ljubljana*	*Luana Boumendil, Université Paris Cité*	*Aaron Sarvet, École Polytechnique Fédérale de Lausanne*	*Silvia Metelli, Université de Paris*
		12.13-12.30: **S17.5 Degrees of necessity and of sufficiency for competing risks survival data** *Andreas Gleiss, University of Vienna*	12.13-12.30: **S18.5 Dynamic interventions determined by recurrent events** *Matias Janvin, Ecole Polytechnique Federale de Lausanne*	12.13-12.30: **S19.5 Analysis of trials with intervention induced post randomisation clustering** *Dawn Teare, Newcastle University*	12.13-12.30: **S20.5 Predicting individualized treatment effects using baseline risk: A simulation study** *Alexandros Rekkas, Erasmusm MC*
12.30-13.30	**LUNCH**				
14.00-17.00	**Social visits:** City Walks around Newcastle Gateshead Victoria tunnels tour Beamish museum visit Hadrian's wall				

Wednesday 24th August 2022

Time	G.41	G.56	G.06	1.17	2.16
09.00-10.30	**Invited 6: Bayesian nonparametrics and ML for causal inference** *22min presentation each* **IN6.1 Assumption-lean Cox regression** Stijn Vansteelandt **IN6.2 Adversarial Monte Carlo Meta-Learning of Conditional Average Treatment Effects** Alex Luedtke **IN6.3 Bayesian nonparametric methods for causal inference** Jason Roy **IN6.4 Nonparametric Bayesian Instrumental Variable Analysis: Evaluating Heterogeneous Effects of Coronary Arterial Access Site Strategies** Sam Adhikari	**Parallel Session 21: Communicating statistical concepts**	**Parallel Session 22: Counterfactuals**	**Parallel Session 23: Bias and Estimation**	**Parallel Session 24: Lightning never strikes twice**
		09.00- 09.18: **S21.1 Why should I? Toward improved communication and evaluation of estimated dynamic treatment strategies** *David Whitney, London School of Hygiene and Tropical Medicine*	09.00- 09.18: **S22.1 Counterfactual simulation to evaluate sequential stratification methods** *Ilaria Prosepe, Leiden University Medical Centre*	09.00- 09.18: **S23.1 Estimation of treatment effects in randomized clinical trials involving external control data** *Heiko Goette, Merck Healthcare KGaA*	09.00- 09.18: **S24.1 Surrogate endpoints in regulatory use: how many are actually statistically valid?** *Wang Pok Lo, University of Edinburgh*
		09.19-09.36: **S21.2 P-value, s-value, b-value, d-value,... What else? Individual Success Probability** *Bernard Francq, GSK*	09.19-09.36: **S22.2 Bias in multivariable Mendelian randomization studies due to measurement error on exposures** *Andrew Grant, University of Cambridge*	09.19-09.36: **S23.2 Performance of different estimators in adaptive two-stage trials with optimized design parameters** *Jan Meis, University of Heidelberg*	09.19-09.36: **S24.2 Application of the R Shiny app DetectoR for signal detection and label generation** *Martin Gebel, Bayer AG*
		09.37-09.54: **S21.3 Statistical advising: professional development opportunities for the biostatistician** *Marissa LeBlanc, University of Oslo*	09.37-09.54: **S22.3 Sequential counterfactual prediction to support individualized decisions on treatment initiation** *Pawel Morzywolek, Ghent University*	09.37-09.54: **S23.3 Considerations for the design and analysis of nested case-control studies** *Monisha Dewan, The Institute of Cancer Research*	09.37-09.54: **S24.3 Internal pilot designs for sample size recalculations in animal experiments - prospects and pitfalls** *Michael Lauseker, Ludwig-Maximilians-Universität München*

		09.55-10.12: **S21.4 The inflation of p-values of likelihood-ratio tests in longitudinal data analysis** *Dominik Grathwohl, Société des Produits Nestlé*	09.55-10.12: **S22.4 Assessing discrimination of counterfactual prediction models for time-to-event outcomes** *Nan van Geloven, Leiden University Medical Centre*	09.55-10.12: **S23.4 Confidence Band for the Cumulative Hazard Rate Function in Right Censored Length-biased Sampling** *Ali Shariati, Macquarie University*	09.55-10.12: **S24.4 Pragmatic SIMEX method to correct for measurement error in time-varying prescription-based exposures** *Steve Ferreira Guerra, McGill University*
		10.13-10.30: **S21.5 Visualising Master Protocols** *Deepak Parashar, University of Warwick*	10.13-10.30: **S22.5 Estimation and calibration of counterfactual risk predictions, with application to liver transplant** *Ruth Keogh, LSHTM*	10.13-10.30: **S23.5 Selection bias and multiple inclusion criteria in observational studies** *Stina Zetterstrom, Uppsala University*	10.13-10.30: **S24.5 Estimating the effects of multiple treatments in combination on outcomes using longitudinal data** *Emily Granger, LSHTM*
10.30-11.00	**BREAK**				
11.00-12.00	**Keynote Speaker:** Prof Bhramar Mukherjee				
12.00-13.30	**LUNCH & AGM – G.06**				
13.30-15.00	**Invited 7: Semi-competing risks and causal inference** *25min presentation each followed by 15min discussion* **IN7.1 Estimands of practical interest in intercurrent event settings** Mats Strensrud	**Parallel Session 25: Simulation and software** 13.30-13.48: **S25.1 Simple – A modular, open-source R software solution to SIMulate PLatform trials Efficiently** *Elias Laurin Meyer, Medical University of Vienna*	**Parallel Session 26: Missing data in Studies** 13.30-13.48: **S26.1 A flexible approach for the analysis of repeated attempt designs** *Mike Daniels, University of Florida*	**Parallel Session 27: Prediction modelling** 13.30-13.48: **S27.1 Effective sample size: a measure of individual uncertainty in predictions** *Doranne Thomassen, Leiden University Medical Center*	**Parallel Session 28: Efficient trial designs** 13.30-13.48: **S28.1 Two one-sided test-then-pool method for clinical trials** *Kazufumi Okada, Hokkaido University*

	IN7.2 A Bayesian nonparametric approach for evaluating the causal effect of treatment in randomized trials with semi-competing risks Daniel Scharfstein **IN7.3 A multistate approach for the study of interventions on an intermediate time-to-event in health disparities research** Linda Valeri Discussant: Els Goetghebeur	13.49-14.06: **S25.2 Simulating binary variables with two levels of clustering** *Rhys Bowden, Monash University*	13.49-14.06: **S26.2 Non-parametric Multiple Imputation for Epoch-level Wearable data in Trials** *Mia Tackney, London School of Hygiene and Tropical Medicine*	13.49-14.06: **S27.2 Automatic detection of glaucomatous neuropathy from fundus images** *Lauren Coan, Liverpool John Moores University*	13.49-14.06: **S28.2 Using the Probability of Longer Survival to Assess the Efficacy of New Cancer Therapies** *Michael LeBlanc, Fred Hutchinson Cancer Center*
		14.07-14.24: **S25.3 A collaborative approach to software development: The crmPack experience** *Oliver Boix, Bayer AG*	14.07-14.24: **S26.3 Targeting hypothetical estimands with causal inference and missing data estimators in a real trial** *Camila Olarte Parra, University of Bath*	14.07-14.24: **S27.3 A comparison of methods for incorporating information from historical prediction models** *Philip Boonstra, University of Michiganorical*	14.07-14.24: **S28.3 Testing for treatment differences with allocation probabilities in response adaptive trials** *Thomas Jaki, MRC Biostatistics Unit*
		14.25-14.42: **S25.4 Simulation Guided Trial Design – The Challenges and The Benefits** *Tom Parke, Berry Consultants LLC*	14.25-14.42: **S26.4 Evaluation of multiple imputation approaches for case-cohort studies with binary outcomes** *Melissa Middleton, Murdoch Children's Research Institute*	14.25-14.42: **S27.4 Comparing methods to generate disease risk factor trajectories for longitudinal microsimulations** *Oliver Church, MRC Biostatistics Unit, University of Cambridge*	14.25-14.42: **S28.4 Determining sample size in a personalised randomised trial comparing a network of treatments** *Becky Turner, MRC Clinical Trials Unit at UCL*
		14.43-15.00: **S25.5 Improving data transparency in the research community by constructing synthetic time-to-event data** *Aiden Smith, University of Leicester*	14.43-15.00: **S26.5 Outcome variances after dropout as an indicator of dropout bias in randomized controlled trials** *Audinga-Dea Hazewinkel, University of Bristol*	14.43-15.00: **S27.5 Dose-response prediction for in-vitro drug combination datasets: a probabilistic approach** *Leiv Rønneberg, MRC Biostatistics Unit, University of Cambridge*	14.43-15.00: **S28.5 Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy** *Jeremy Taylor, University of Michigan*

15.00-15.30	BREAK				
15.30-17.00	**Parallel Session 29: Joint inference with high dimensional data**	**Parallel Session 30: Machine learning and prediction**	**Parallel Session 31: Early Phase Trials**	**Parallel Session 32: Complex Modelling**	
	15.30-15.48: **S29.1 Bayesian variable selection with applications to selection of comorbidities** *F. Javier Rubio, University College London*	15.30-15.48: **S30.1 Deep Survival EWAS modeling of cancer time to diagnosis via blood-derived DNA methylation profiles** *Francesca Ieva, Politecnico di Milano*	15.30-15.48: **S31.1 Decision making under uncertainty in PI-II dose finding trials in Oncology** *Andrew Hall, University of Leeds*	15.30-15.48: **S32.1 Flexible parametric methods for calculating life expectancy in small populations** *Freya Tyrer, University of Leicester*	
	15.49-16.06: **S29.2 A scalable ECM algorithm for multiple-network joint inference with the graphical horseshoe** *Camilla Lingjaerde, MRC Biostatistics Unit, University of Cambridge*	15.49-16.06: **S30.2 A Comprehensive Framework for the Evaluation of Individual Treatment Rules From Observational Data** *Francois Grolleau, Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité*	15.49-16.06: **S31.2 Beyond 3+3 – acceptability and implementation of model-based dose-finding study designs in practice** *Helene Thygesen, University of Glasgow*	15.49-16.06: **S32.2 Functional Limits of Agreement using a Mixed Effects Modelling Framework in Method Comparison Study** *Kishor Das, National University of Ireland*	
	16.07-16.24: **S29.3 A Natural History and Copula Based Joint Model for Regional and Distant Breast Cancer Metastasis** *Alessandro Gasparini, Karolinska Institutet*	16.07-16.24: **S30.3 Quantifying instability after developing a clinical prediction model** *Richard Riley, Keele University*	16.07-16.24: **S31.3 Advanced tumor metrics to support characterization of the dose-response relationship** *Cornelia Ursula Kunz, Boehringer Ingelheim Pharma GmbH & Co. KG*	16.07-16.24: **S32.3 Progression models for imaging data with Longitudinal Variational Auto Encoders** *Benoît Sauty, INRIA*	

	16.25-16.42: **S29.4 Marker selection in joint analysis with competing risks: application to SARS-COV-2 patients** *Alexandra Lavalley-Morelle, Université Paris Cité*	16.25-16.42: **S30.4 History-Restricted MSM and LCGM of Treatment Trajectories for a time-dependent outcome** *Awa Diop, Laval University*	16.25-16.42: **S31.4 Improving interim decision in two-stage phase II designs by incorporating short-term endpoints** *Dario Zocholl, Charité Universitätsmedizin Berlin*	16.25-16.42: **S32.4 Modelling the effect of time varying covariates in time to event studies of twins with delayed entry** *Annah Muli, University of Leeds*	
	16.43-17.00: **S29.5 Modelling dynamic associations in multivariate longitudinal data** *Roula Tsonaka, Leiden University Medical Center*	16.43-17.00: **S30.5 Flexible parametrization of individual sparsified networks for prediction: a proof-of-concept** *Mariella Gregorich, Medical University of Vienna*	16.43-17.00: **S31.5 Aggregating prior distributions from experts for sample size calculations** *Nina Wilson, Newcastle University*	16.43-17.00: **S32.5 Quantitative prediction error analysis to investigate performance under measurement heterogeneity** *Kim Luijken, Leiden University Medical Center, Utrecht*	
19.00-23.00	**Conference Dinner** Civic Centre Newcastle				

Thursday 25th August 2022

Time	Symposium	Symposium	ECB Day
09.00-10.30	Mini symposium 1: STRATOS	Mini symposium 2: Modern software tools for modern statistics	ECB Day
10.30-11.00	**BREAK**		
11.00-12.30	Mini symposium 1: STRATOS	Mini symposium 2: Modern software tools for modern statistics	ECB Day